Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Stock Slumps 8.13 Percent on Q1 Revenue Shortfall, Net Loss

NEW YORK, May 5 (GenomeWeb News) - Shares in Third Wave Technologies were down 8.13 percent, or $.39, at $4.41 in mid-afternoon trading after the company today reported a sharp downturn in revenues and a net loss for the first quarter of 2005. The stock fell as low as $3.86 early in the day.


As GenomeWeb News reported this morning, Third Wave's revenues for the three months ended March 31 fell to $7.1 million from $15.3 million during the same quarter in 2004. Third Wave attributed the shortfall to a lack of research revenue, a delay by one of its suppliers, and "performance issues" with an instrument from Roche that is required for Third Wave's HCV genotyping analyte-specific reagents.


"As expected, our research revenue will continue to be lower than it has been historically," CEO John Puisis said in a company statement. "We believe the temporary delays that impacted our molecular diagnostic revenue in the first quarter have been remedied."


Research and development costs stayed flat at $2.5 million compared to $2.7 million during last year's first quarter.


Third Wave recorded a net loss of $4.4 million, or $.11 per share, compared to net earnings of $2.8 million, or $.07 per share, during the same quarter last year.


As of March 31, Third Wave had $64.5 million in cash, cash equivalents, and short-term investments.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.